Page 1,776«..1020..1,7751,7761,7771,778..1,7901,800..»

Category Archives: Transhuman News

American Horror Story: The 100-Year Life – Seeking Alpha

Posted: June 3, 2017 at 12:01 pm

You think we have a retirement crisis now? Just wait. The worst impact will be to the 20 somethings and 30 somethings, and it has nothing to do with the funding of Social Security (at least not directly). I can't even comprehend my granddaughter's (age 5) generation.

Consider the fact that for more than 200 years life expectancy in developed countries (you can argue that's us) has increased 2 or 3 years every decade. Research complied by London School of Business professors Lynda Gratton (Management Practice) and Andrew Scott (Economics) show that most children born in the West (us) will live past their 100th birthday. This is not climate change, folks: there is no debate allowed here.

While human longevity has been happening all along, we build our life stages and plan our retirements around the same assumptions our parents and grandparents did. Consider Social Security, conceived in 1935 when folks were expected to work until they retired at 65 years old, and died at age 67. Forget about anything like funding shortfalls in 2038. It was and is not equipped to deal with a 40 year retirement. NOTE: LIFE EXPECTANCY FOR CHILDREN BORN IN 1930 WAS 58 FOR MEN AND 62 FOR WOMEN. Chew on that in the context of the creation of the Social Security System.

Professors Scott and Gratton wrote a dramatic book (best book I ever read not written by Kurt Vonnegut), THE 100 YEAR LIFE, published June 2, 2016. Everyone should read it.

They state that the gift of longevity carries with it the curse of having to cope with it financially and socially. They call for "deep seated social change" to occur at the economic, social, political, business and individual level. From the book: "We either can't afford to retire at the age our parents did or will have to work for so long that our mental and physical fitness as well as our enthusiasm for life could suffer. Individuals, companies and governments all have a role to play in ensuring we structure our lives differently so we can make the most of a longer life."

For those in their 40s-60s they advise, "Failure to innovate in response to a longer life will mean stresses and strains in your life as existing models are stretched uncomfortably over a 100 years."

Most of us over 50 have been and are ingrained in a three stage life: Education/training, career/work to accumulate, and retirement. This model will not and cannot hold. Professors Scott and Gratton predict we will have to move to a multi stage life, with perhaps several different career paths combined with pauses in between. They call it "individualized sequencing." Retirement will be in your 80s, if at all.

For those in their 20s, think in terms of delayed saving for retirement, delayed accumulation careers, life experience enjoyment earlier and periodically along the way. This is not a rose-colored glasses wish; it is happening now. The 20 and 30 year olds currently are saving little now and enjoying life more. Now. They are embracing the multi stage life, maybe without even knowing it. While we old folks may cringe at this and say "how frivolous," we are wrong. They are right.

Think of the business impacts. Human Resources needs to be refocused, careers have to be redefined, and the work-life balance made more flexible. Established corporations are built around the three stage life. Mark Zuckerberg and Elon Musk businesses, maybe not. After all, they're innovators.

Governments need to move toward "lifetime measures rather than age specific policies. It has to address "pensions, education, relationships, families, households and career breaks."

Think of the impact on financial firms, insurance companies (think what Long Term Care insurance will have to look like), healthcare systems (do you think your premiums will go down?), education institutions, recreation, retirement communities. The list is almost unending. It will have to be a massive total overhaul of the entire social infrastructure.

And what about personal finance in the days of the 100 Year Life?

My learned friend and colleague, Steve Barger says, "No one is preparing today's children or young adults for the probability that they will live to 100 or beyond. Living longer changes everything we do -early education, extended work, recreation, health care, financial responsibilities, retirement targets, re-training for new skills and learning new information possibly at age 75.

The primary source for life preparedness (our educational institutions K - 16+) are so blinded by political correctness that they have completely ignored one of life's critical survival skills: managing one's wealth.

There is not one college or university in this country that requires 'personal financial proficiency' in order to graduate. Where are our educational leaders? Nowhere to be found. How selfish and thoughtless. You should be ashamed."

What does it mean for me? I won't be around to see the upheaval.

What does it mean for my kids (38-42)? They're thinking and saving and have already foregone traditional careers for more creative, holistic ones.

What does it mean for my grandchildren (5-14-16)? They WILL live that multi stage life, starting with "do it now" (whatever "it" is).

What does it mean for you? Our ancestors were artisans. Think about learning a trade, no matter what age.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Quotes from THE HUNDRED YEAR LIFE by London School of Business Professors Andrew Scott and Lynda Gratton, Published June 2, 2016, and Steve Barger.

Link:
American Horror Story: The 100-Year Life - Seeking Alpha

Posted in Human Longevity | Comments Off on American Horror Story: The 100-Year Life – Seeking Alpha

Dermatitis | DermNet New Zealand

Posted: at 12:00 pm

Home Topics AZ Dermatitis

Author: DrAmanda Oakley, Dermatologist, Hamilton, New Zealand,1997.

Dermatitis refers to a group of inflammatory conditions. It affects the outer layer of the skin, the epidermis.

Dermatitis affects about one in every five people at some time in their lives. It results from a variety of different causes and has various patterns.

The terms dermatitis and eczema are often used interchangeably. In some cases the term eczematous dermatitis is used. Dermatitis can be acute or chronic or both.

An in-between state is known as subacute eczema.

Psychological stresses can provoke or aggravate dermatitis, presumably by suppressing normal immune mechanisms.

Treatment of dermatitis

An important aspect of treatment is to identify and tackle any contributing factors (see above).

Dermatitis is often a long-term problem. When you notice your skin getting dry, moisturise your skin again and carefully avoid the use of soap. If the itchy rash returns, use both the moisturiser and the steroid cream or ointment. If it fails to improve within two weeks, see your doctor for further advice.

Donate Today

Help us to update and maintain DermNet New Zealand

Go here to see the original:
Dermatitis | DermNet New Zealand

Posted in Eczema | Comments Off on Dermatitis | DermNet New Zealand

Topical Steroids : National Eczema Society

Posted: at 12:00 pm

For some people with eczema, the regular use of emollients is all that is needed to keep the condition under control. However, for many people there will be a time when a steroid preparation is required as part of their treatment in order to bring an eczema flare under control. Topical steroids are the most common treatment for eczema flares. This is when eczema becomes red, sore and very itchy. Topical steroids are used in short treatment bursts and should be used in conjunction with emollients. Emollients for washing, cleansing and moisturising are essential to a good skin care routine for treating and preventing dry and itchy skin.Emollients need to be used all the time. For more information on emollients click here. What are topical steroids?

Topical means something that is applied to the skin. Steroids are a group of natural hormones, produced in the body by a variety of different glands. They are also produced synthetically as medicines. The topical steroids used for treating eczema are totally different from steroids used in contraceptive pills or for bodybuilding.

Topical steroids are a valuable tool in the management of eczema. They reduce redness and soreness (inflammation) and can be very effective in controlling flare-ups, as they make the skin less itchy and sore, giving it a chance to heal.

Topical steroids are mostly prescribed to treat eczema flares. In this case, you will generally be instructed to apply topical steroid for short bursts of treatment, and then stop or step down use when the eczema flare settles. If you are prescribed a milder steroid you will generally be told to stop after a burst of treatment; but if you are prescribed a stronger steroid, you may be instructed to step down back to lower potency preparations as your eczema flare settles.

Sometimes people with more severe eczema whose eczema flares very frequently are prescribed topical steroids to apply on 2 consecutive days a week on the areas where their eczema usually flares. This is known as weekend therapy and can help to prevent the almost continuous flare cycle, meaning that in the long run less topical steroid would be needed to control the eczema than if each flare were treated as it occurs.

You will generally be advised to apply your topical steroid 12 times a day to areas of active eczema i.e. where it is flaring. (NICE Guidelines for children under 12 years recommend once a day.)

It is important to use the correct amount of topical steroid for your eczema, as instructed by your healthcare professional. Topical steroids should be applied with clean hands so that the skin just glistens. It can sometimes be difficult to judge how much steroid to use and there are guidelines on the amount required to cover body areas that are affected by eczema. These are based on the Finger Tip Unit (FTU), and explained in detail in our fact sheet which you can download as a pdf from the related documents to the right of this page.

There are no standard rules regarding whether to apply a steroid preparation after or before using an emollient. However, whichever order of care you choose it is important to leave as long a period as practical, of around 30 minutes, between the two treatments.

You may be given more than one topical steroid to treat your eczema; for example a milder steroid may be prescribed for the face or genital area and a stronger steroid for other parts of the body. Make sure that you are clear which preparation to use on which part of the body. If in doubt talk to your pharmacist /nurse or contact your doctor.

In the UK topical steroids come as ointments, creams, lotions, scalp applications and impregnated tape/plasters and in four different strengths:

Mild

Moderately potent

Potent

Very Potent.

In deciding which type you need, your doctor should take account of your age, the severity of the eczema, where it occurs and any other treatments you are using. Milder preparations are usually used for the face, genital areas or on babies.

The period of time a steroid may be used depends upon the severity of the eczema and the potency of the topical steroid. Your healthcare professional will advise you on this.

Some topical steroids have added ingredients and are sometimes prescribed where eczema is infected.

If you download our topical steroids factsheet look under related documents to the right of this page you will find tables listing the topical steroids currently available in the UK showing their potencies also which ones have added ingredients. Bear in mind that outside the UK treatments with the same or a very similar name may have different active ingredients and be of a different potency.

Topical steroids, used appropriately and under supervision, are a safe and effective treatment for eczema. The likelihood of side effects occurring is directly related to the potency of the preparation, where it is being used, and the condition of the skin on which it is used and the age of the person concerned. All these factors should be taken into consideration when a prescription is given to treat eczema.

Hydrocortisone 0.05%, 0.1%, 0.5% or 1% is extremely unlikely to cause adverse effects and can be used as prescribed on the face and in young children. Be careful not to confuse this with hydrocortisone butyrate, which is a potent topical steroid.

If used inappropriately or over long periods of time, topical steroids can thin the skin; blood vessels may become more prominent, and the skin can lose its elasticity, developing stretch marks. Other possible side effects include increased hair growth of very fine hair and perioral dermatitis (i.e. a spotty rash around the mouth).

Topical steroids have been in widespread use for over 50 years and although side effects can occur, as explained in our fact sheet available to download from the right of this page, this is usually because treatment has been used incorrectly. Under the supervision of a doctor, and used properly and sensibly in combination with good skincare as part of an overall management routine, topical steroids are a valuable treatment for eczema.

Read the original:
Topical Steroids : National Eczema Society

Posted in Eczema | Comments Off on Topical Steroids : National Eczema Society

Fend off Psoriasis and Eczema with Simple, Inexpensive …

Posted: at 12:00 pm

Eczema (atopic dermatitis), and the closely associated psoriasis, are two very common skin problems.

Both eczema and psoriasis are potentially allergic conditions that can be triggered by environmental factors and dozens of other external irritants like:

While psoriasis is most often linked with external allergic triggers, eczema is often caused by food allergies.

However, although theyre different diseases and have varying triggers, their treatments have many commonalities. .

Eczema is the itch that rashes, meaning, theres really no rash until you start scratching the itchy area. Hence, the first thing you need to do is to stop scratching!

Addressing the itch -- As anyone with eczema will attest, this is easier said than done. But fortunately, there IS a really simple, inexpensive way to relieve the itch: Simply put a saltwater compress over the itchy area.

Youll want to use a high quality natural salt, such as Himalayan salt. Simply make a solution with warm water, soak a compress, and apply the compress over the affected area. Youll be amazed to find that the itching will virtually disappear!

Another method that can be helpful for reducing or stopping the itch is EFT.

Proper skin hydration When working with any type of skin condition, you need to make sure your skin is optimally hydrated. Skin creams are rarely the answer here, but rather youll want to hydrate your skin from the inside out by consuming high quality, animal-based omega-3 fats in your diet.

Your best sources for omega-3s are animal-based fats like krill oil or fish oil. I also find it helpful to include a bit of gamma linoleic acid, typically in the form of primrose oil, as this works remarkably well for eczema. Products like krill for women are good for both sexes for this condition as they have both fatty acids.

Plant-based omega-3s like flax and hemp seed, although decent omega-3 sources in general, will not provide the clinical benefit you need to reduce inflammation and swelling in your skin.

Secondly, youll want to reduce your exposure to harsh soaps and drying out your skin with excessive bathing. Use a very mild soap when you cleanse your skin, especially in the winter to avoid stripping your skin of moisture.

Taking care of your gut = Taking care of your skin Many dont realize this, but the health and quality of your skin is strongly linked to the health of your gut. I recommend taking a high quality probiotic to ensure optimal digestive health. Fermented foods can be used as well, but are neither as common nor as easy to use.

Diet and skin quality Food allergies play an enormous role in eczema. In my experience, the most common offending agent is wheat, or more specifically, gluten. Avoiding wheat and other gluten-containing grains is therefore a wise first step.

If you were to visit my clinic outside of Chicago as a new patient, one of the first steps we would advise would be to go on a gluten-free diet for a number of weeks and carefully observe any health improvements. This is an enormously common problem and many of our patients are surprised to find how much improvement they actually achieve from this step.

Avoiding grains will also reduce the amount of sugar in your system, which will normalize your insulin levels and reduce any and all inflammatory conditions you may have, including inflammation in your skin.

Other common allergens include milk and eggs. I recommend you do an elimination trial with these foods as well. You should see some improvement in about a week, sometimes less, after eliminating them from your diet if either of them is causing you trouble.

Basking in the sun Vitamin D in the form of sun exposure is your best friend when dealing with either of these skin conditions, but its especially helpful for psoriasis.

I produced a one-hour lecture that explains the health benefits of this long under-appreciated vitamin, so if you havent seen it already, I strongly recommend you take the time to watch this free video now.

Ideally, youll want to get your vitamin D from appropriate sunshine exposure because UVB radiation on your skin will not only metabolize vitamin D, but will also help restore ideal skin function. High amounts of UVB exposure directly on affected skin but not so much to cause sunburn! will greatly improve the quality of your skin.

However, if you cant get sufficient amounts of sun during the winter months, a high quality safe tanning bed can suffice. A safe tanning bed will provide the optimized forms of UVA and UVB wavelengths, without dangerous magnetic skin balance.

You dont have to use expensive, dangerous medicines to treat eczema or psoriasis!

Steroid creams especially, are clearly something youll want to avoid, because although they work initially, you will tend to rapidly develop tolerance to them. These creams contain synthetic steroids, which are absorbed into your skin, and can wreak serious havoc with your adrenal system.

So please, avoid steroid creams and other potentially dangerous medications for these skin conditions and use these natural methods instead. Youll find they work almost all the time, especially if you diligently apply them.

Go here to see the original:
Fend off Psoriasis and Eczema with Simple, Inexpensive ...

Posted in Eczema | Comments Off on Fend off Psoriasis and Eczema with Simple, Inexpensive …

Does Diet Affect Eczema Treatment? – Care2.com

Posted: at 12:00 pm

There are many recognized triggers of eczema.

However, the role that diet plays is a murky area of research.

This article reviews the current evidence surrounding eczema treatment.

What is Eczema?

Eczema, also referred to as atopic dermatitis (AD), is a chronic and recurrent inflammatory skin condition that causes itchy, red, and swollen patches of skin.

Unlike psoriasis, eczema most often appears on the inside of the elbows and knees.

There are numerous types, butinfantile eczemais the most common developing in 1 in 5 infants (1).

However, know that eczema can affect anyone at any age. In fact, 334 million people worldwide were said to have eczema in 2013, and 10-30% of people in the U.S (2).

Unfortunately, rates have increased by 2 to 3-fold in Western countries over the past few decades (3).

Summary: Eczema is a common inflammatory skin condition, and rates are on the rise. The most common type is infantile eczema (occurs in children less than 5 years old).

What are the Causes of Eczema?

Several factors contribute to the likelihood of developing eczema.

Eczema risk factors include:

Summary: Many factors increase the risk of eczema including genetics, gender and immune abnormalities. Eczema is not an allergy but has many overlapping symptoms.

Conventional Eczema Treatment

Despite no known cure for eczema, various treatments are available to manage and prevent flare ups.

Dermatologists treat severe eczema with topical (on the skin) or oral medications and phototherapy. Milder cases require skin care and lifestyle modifications (8).

Commonly prescribed medications include anti-histamines, antibiotics, and corticosteroids (oral or topical). Unfortunately, these treatments also have undesirable side effects and lack long-term relief.

Those with eczema are also typically instructed to avoid common triggers including:

Summary: Eczema has no cure, but there are useful strategies for treating and preventing future flare-ups. Alongside medication, common triggers to avoid include dry climates and high stress levels.

Dietary Triggers to Eczema

Current research is unclear about the connection between eczema and specific food triggers.

Food Allergies and Eczema

Those with eczema are more likely to have food allergies, particularly in children under the age of 3 or 4.

Common food allergies in children with eczema include cows milk, eggs, peanuts, soy, wheat, cod/catfish and cashew.

Studies suggest the connection between childhood food allergy and eczema is 33 to 63%. Adult onset eczema is less likely linked with food allergy at a rate of 10%. However, this does not mean that food allergies cause eczema (10, 11).

Additionally, age reduces the likelihood that food allergy contributes to eczema, as most children outgrow their food allergies (12).

The exception is adults with a birch pollen allergy. One study found their eczema was triggered by foods that cross-react with birch pollen like green apples, carrots, hazelnuts, celery, and pears (13).

Therefore, if you have a birch pollen allergy and eczema, consider removing these foods from the diet.

Food Sensitivities and Eczema

IgE-mediated food allergy testing may have poor reliability in those with eczema.

Adults with eczema typically dont suffer from classic food allergies (i.e. IgE-mediated allergy), but rather experience delayed reactions after eating certain foods. This type of reaction is a delayed food hypersensitivity, also referred to as a food sensitivity.

Presently, there is no gold-standard test for diagnosing food sensitivities. Therefore, if you suspect food sensitivities trigger your eczema, consider keeping a food/symptom diary and working with a healthcare provider to identify problematic foods (14).

Pseudoallergens and Eczema

The connection between pseudo-allergens like food additives, histamine, salicylates and benzoates triggering eczema is controversial (15).

While the reason is still unclear, its theorized that these chemicals can cause inflammation in mast cells, a type of white blood cell. Those with eczema have higher levels of mast cells in the areas of skin with the rash (15).

One double-blind-placebo-controlled study on 50 adults found that 63% benefited from a 6-week low-pseudo-allergen diet. This diet avoided all foods containing preservatives, dyes and or antioxidants (16).

Celiac Disease and Eczema

Those with celiac disease (CD) are 3 times more likely to suffer from eczema (17).

Even relatives of those with CD are twice as likely to have eczema. This connection is based on the possible role of autoimmunity causing eczema (18).

Summary: Childhood eczema is more likely associated with food allergies compared to adult eczema. If you have birch pollen allergy or celiac disease, removing cross reactive foods and gluten helps.

Eczema Elimination Diet

Elimination diets are commonly recommended to help identify dietary triggers for a specific symptom.

A low FODMAP diet for food intolerance is the obvious example.

In this case it can be used as a home remedy of sorts for eczema treatment.

Following an elimination diet for 4 to 6 weeks may be beneficial for eczema sufferers. Remove all possible trigger foods and notice any changes in the skin (19).

There is no standardized elimination diet for this condition, but consider developing a plan based on your suspected trigger foods.

Below is a list of eczema trigger foods to help you get started.

Monitor eczema symptoms after strict avoidance of these suspected foods. While changes in symptoms may be coincidental, presence of food hypersensitivities could also explain the change.

Thereafter, carefully rechallenge the avoided foods back into the diet, ideally under the supervision of a dietitian or other health professional. When challenging foods, allow a few days between trials for the development of delayed symptoms (12).

This rechallenge plan for those on a low FODMAP diet may help you better visualize the concept.

Keep in mind that eczema has multiple causes and triggers. An elimination diet is not appropriate for everyone, so talk to your doctor or dietitian before starting one.

Summary: Some eczema sufferers may benefit from trialing a 4 to 6-week elimination diet based on their health history. Be sure to undergo this plan with the supervision of a healthcare professional.

Other Home Remedies for Eczema

Sometimes a change in diet does not provide much help.

Many search for other natural approaches instead:

Summary: There are many other natural therapies to help relieve eczema, however the evidence on most is limited. Consider these only after consulting with your doctor.

Treating Eczema Is Complex

Eczema is a complex inflammatory skin condition.

Its most common in children, but can develop at any age.

Conventional treatment options are available, yet dont offer long-term relief or a cure.

Unfortunately, there are no solid dietary recommendations either. Removing any known food allergies or sensitivities is a good place to start, which is best done through a structured elimination diet.

There are certain probiotic strains that are also worth exploring if you are struggling with symptoms.

Until we know more, its important you pay close attention to your body and notice if there are any specific dietary triggers for you.

This post originally appeared on Diet vs Disease as Does Diet Affect Eczema Treatment?

Disclaimer: The views expressed above are solely those of the author and may not reflect those of Care2, Inc., its employees or advertisers.

Originally posted here:
Does Diet Affect Eczema Treatment? - Care2.com

Posted in Eczema | Comments Off on Does Diet Affect Eczema Treatment? – Care2.com

5 Foods That Fight Dry Skin from the Inside Out – Health.com

Posted: at 12:00 pm

Whether your skin gets cracked and flaky in extreme cold or you struggle with it year-round, dry skin can be the worst. Sure, you can stock up on lotions, buy hydrating makeup, or try out a super-hydrating face serum.

But what you eat can also make a big difference when it comes to easing dry skin. No, were not talking about our DIY pumpkin or avocado face masks (although those are ultra-hydrating too!). Instead, adding certain foods to your diet can moisturize and replenish skin from the inside out. Watch this video to learn about the top five foods that fight this stubborn condition.

WATCH THE VIDEO: 5 Things You Didn't Know You Could Do With an Avocado

No time to watch? Heres a rundown of the best foods for dry skin, plus the reasons theyre so awesome:

Olive oil: This plant-based oil helps skin retain water, making it more supple.

Watermelon: The lycopene that gives this sweet treat its pink-red color also helps stave off UV damage, which in turn leads to wrinkles and dryness.

Avocado: This trendy fruit is full of oleic acid, a fatty acid that helps skin retain moisture and plumpness.

Salmon: Its high level of omega-3 fatty acids help boost hydration and prevent acne. Plus, it can help protect skin from the drying effects of sun exposure.

Strawberries: Loaded with vitamin C (each serving has more than a grapefruit or orange), they help prevent wrinkles and age-related skin dryness.

View original post here:
5 Foods That Fight Dry Skin from the Inside Out - Health.com

Posted in Eczema | Comments Off on 5 Foods That Fight Dry Skin from the Inside Out – Health.com

Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients – Medical Xpress

Posted: at 12:00 pm

June 2, 2017

Psoriasis is an incurable chronic disease with a hereditary component, in which the body's immune system attacks parts of the skin. This leads to scaly red patches, which can be very itchy. About two million people in Germany have psoriasis, and 400 000 of them have a moderate to severe form of the disease.

Since 2015, the monoclonal antibody secukinumab (trade name: Cosentyx) has been approved for patients with moderate to severe plaque psoriasis. Since 2016, the monoclonal antibody ixekizumab (trade name: Taltz) has also been approved. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these drugs offer an added benefit for patients in comparison with the appropriate comparator therapies. For both drugs, there are indications of considerable added benefit for certain patients.

Secukinumab: drug manufacturer submitted new dossier for one patient group

The older of the two drugs had already undergone an early benefit assessment in 2015. At that time, IQWiG had derived indications of a minor and of a non-quantifiable added benefit - but only for patients with no or inadequate response to previous systemic treatments or with contraindication or intolerance to such treatments. There are also those patients who are candidates for systemic treatment, but who have not yet received such treatment. The manufacturer applied for a new benefit assessment for this group because of new scientific findings.

No negative effects

For this new early benefit assessment, the manufacturer presented data from the study PRIME, in which fumaric acid esters were used in the comparator arm. In comparison with this comparator therapy, secukinumab showed very large positive effects in remissions, which resulted in an indication of an added benefit.

In addition, there was a hint of an added benefit in health-related quality of life and hints and indications of lesser harm in some side effects. There were no negative effects in any outcome. In summary, this resulted in an indication of considerable added benefit of secukinumab in patients who are candidates for systemic treatment.

Ixekizumab: only one of both studies usable

The other drug, ixekizumab, has been approved since 2016, but was not introduced into the market and subjected to an early benefit assessment before now because the manufacturer wanted to wait for new study results for this drug as well. The Federal Joint Committee (G-BA) again distinguished between two patient groups: patients who can receive systemic and/or phototherapy and patients with no or inadequate response to previous systemic treatments.

IQWiG could only analyse the data for the latter patient group because numerous participants who had already had phototherapy, i. e. a systemic treatment, had apparently been included in the study submitted by the manufacturer for patients eligible for systemic treatment. This specific research question of the benefit assessment can only be answered on the basis of patients who have not received previous systemic treatment, however.

Large positive effects also for this drug

For patients with no or inadequate response to previous systemic treatments, ixekizumab was compared with ustekinumab in the study IXORAS. The study is ongoing; data are available from an interim analysis after 24 weeks. Since there were notably more remissions under ixekizumab than in the comparator arm, there is an indication of a considerable added benefit in the outcome category "morbidity".

There is an indication of a minor added benefit for health-related quality of life. This is accompanied by an indication of greater harm in the outcome "general disorders and administration site conditions", which does not raise doubts about the positive effects, however. In the overall consideration, there is an indication of a considerable added benefit of ixekizumab in comparison with ustekinumab for adults with moderate to severe plaque psoriasis with no or inadequate response to previous systemic treatments.

Symptom analysis inadequate for course of the disease

"Both assessments show that there are notable advances for patients also outside oncology", says the Institute's Deputy Director Stefan Lange in view of the results. "This is good news. We have one suggestion for improvement, however: In both studies, disease-related symptoms were analysed only for fixed time points and only improvements were reported. This is inadequate for the typical course of the disease with its ups and downs. It would be better to present and analyse the burden of symptoms for each patient over the total study duration. There are simple methods for this purpose. This would also make temporary flare-ups and permanent improvements or deteriorations visible, which are generally of greater importance to the patients than their condition on a single fixed day."

G-BA decides on the extent of added benefit

The dossier assessments are part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessments, the G-BA conducts commenting procedures and makes final decisions on the extent of the added benefit.

Explore further: Secukinumab in plaque psoriasis: Manufacturer dossier provided no hint of an added benefit

More information: More English-language information will be available soon (extracts of the dossier assessments as well as easily understandable information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.

Secukinumab (trade name: Cosentyx) has been approved since January 2015 for adults with moderate to severe plaque psoriasis. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...

Pembrolizumab (trade name: Keytruda) was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell ...

Secukinumab (trade name: Cosentyx) has been approved since November 2015 for adults with active ankylosing spondylitis or psoriatic arthritis. For patients with plaque psoriasis, the drug already underwent an early benefit ...

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. In a ...

The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the trade name Genvoya since November 2015 as treatment for adults and adolescents aged over ...

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute ...

In response to the rise in opioid overdose deaths nationwide, pharmaceutical companies have developed formulations of prescription opioids designed to prevent tampering or abuse. These "abuse-deterrent" forms, however, are ...

Almost one-third of new drugs approved by U.S. regulators over a decade ended up years later with warnings about unexpected, sometimes life-threatening side effects or complications, a new analysis found.

(HealthDay)EpiPensdevices used to rescue people during a severe allergic reactioncan remain effective years after their expiration date, a new study reports.

Top promoted drugs are less likely than top selling and top prescribed drugs to be effective, safe, affordable, novel, and represent a genuine advance in treating a disease, argue US researchers in The BMJ today.

A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found that physicians in academic medical centers (AMCs) prescribed fewer of the promoted drugs, and more non-promoted ...

A car crash shattered Stuart Anders' thigh, leaving pieces of bone sticking through his skin. Yet Anders begged emergency room doctors not to give him powerful opioid painkillershe'd been addicted once before and panicked ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original here:
Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients - Medical Xpress

Posted in Psoriasis | Comments Off on Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients – Medical Xpress

Coal tar: an anti-inflammatory treatment for psoriasis – Clinical Advisor

Posted: at 12:00 pm


Clinical Advisor
Coal tar: an anti-inflammatory treatment for psoriasis
Clinical Advisor
Coal tar products are most often used topically for a variety of skin conditions, including psoriasis. Coal tar is one of the oldest known treatments for psoriasis, as it reduces scaling, itching, and inflammation. Its exact working mechanism is not known.

Excerpt from:
Coal tar: an anti-inflammatory treatment for psoriasis - Clinical Advisor

Posted in Psoriasis | Comments Off on Coal tar: an anti-inflammatory treatment for psoriasis – Clinical Advisor

Prepping for FDA filing, Loxo rolls up data on its site-agnostic cancer med larotrectinib – FierceBiotech

Posted: at 11:59 am

CHICAGOWhen Merck & Co.s Keytruda won approval last week to treat tumors based on a common biomarkerrather than the location in the body where the tumor originated, talk was thatthe true start of precision medicine had arrived.

The $1.3 billion market cap biotech Loxo Oncology is hoping to be a part of that journey. At the American Society of Clinical Oncology meeting Saturday, Loxo posted the latest data for its experimental larotrectinib (LOXO-101), amedicationit hopes will treat an array of cancers innearly a dozen sites across the body.

The data showed that 50 larotrectinib patients withtumors harboring tropomyosin receptor kinase (TRK) fusions had a 76% objective response rate (ORR) across tumor types. The drug met its primary endpoint; key secondary endpoints, including progression-free survival and duration of response, had not yet been reached.

The data drewfrom three trials, a phase 1 study in adults, a phase 2 study called Navigate, and a phase 1/2 pediatric trial called Scout.The results were based on the intention-to-treat principle, using the first 55 TRK fusion patients enrolled to the three trials, regardless of their prior therapy or tumor-tissue diagnostic method.

In all, 44 adults and 12 younger patients were enrolled, with tumors identified by 14 different lab tests. The TRK fusion patients carried a host of primary diagnoses, including appendiceal cancer, breast cancer, cholangiocarcinoma, colorectal cancer, gastrointestinal stromal tumor, infantile fibrosarcoma, lung cancer and more.

The confirmed overall response rate was 76% in 50 patients, with these rates generally consistent across tumor types, TRK gene fusions, and various diagnostic tests, Loxo said in a statement.

In the pediatric setting, larotrectinib also showed promising activity in the presurgical management of patients with infantile fibrosarcoma, with three patients treated to best response.

The drug, developed in partnership with Array Biopharma,has a breakthrough designation from the FDA to treat children and adults with metastatic or inoperable solid tumors that test positive for the TRK biomarker, and who've either failed on previous treatments or have no acceptable alternatives.

In the safety department, Loxo says that seven(13%) of the study patients had their doses reduced because of side effects, but no patients stopped taking larotrectinib after suffering side effects.

All patients whose doses were lowered experienced tumor regression, which then continued on the reduced dose. Nearly all of the dose reductions were due to infrequent neurocognitive adverse events, likely a result of on-target TRK inhibition in the [central nervous system], Loxo explained.

Loxo added that sixpatients responded to larotrectinib but later progressed, a pattern referred to as acquired resistance.

The company is gathering other evidence forlarotrectinib'sapplication for FDA approval, slated for late this year or early next. Acentral, independent radiology review will be performed in the second half of 2017, and Loxo plans to announce that data before the end of the year. A separate assessment by independent radiologists, not yet conducted, will also be required to support its regulatory filing, the companynotes.

TRK is a neuron-stimulating factor that is active in fetal development but has its expression switched off later in life. In some cases, the TRK gene can fuse with other genes and reactivate, causing various forms of cancer.

Loxo's development program for the drug is agnostic to any particular tumor type, focusing instead on recruiting patients whose cancer cells express the TRK gene. If approved, the drug could be prescribed across multiple solid tumor types on the strength of genetic testing for neurotrophic TRK (NTRK) fusion proteins, which it will do with the help of Roche.

RELATED: Merck's Keytruda wins first FDA nod to treat genetically ID'd tumors anywhere in the body

NTRK mutations crop up in a small percentage of patients with any particular cancer, but they add up. The company estimated last year that between 1,500 and 5,000 late-stage cancer patients could be eligible for treatmentin the U.S. each year, with a similar number in Europe.

[T]he larotrectinib TRK fusion story fulfills the promise of precision medicine, where tumor genetics rather than tumor site of origin define the treatment approach," said David Hyman, lead investigator in the Navigate trial and chief of the early drug development service at Memorial Sloan Kettering Cancer Center."It is now incumbent upon the clinical oncology and pathology communities to examine our testing paradigms, so that TRK fusions and other actionable biomarkers become part of the standard patient workup."

The company also has two follow-up candidatesLOXO-292 and LOXO-195which target other cancer-causing genes resulting from fusions with kinase genes.

Original post:
Prepping for FDA filing, Loxo rolls up data on its site-agnostic cancer med larotrectinib - FierceBiotech

Posted in Gene Medicine | Comments Off on Prepping for FDA filing, Loxo rolls up data on its site-agnostic cancer med larotrectinib – FierceBiotech

Carleton College to hold its 143rd Commencement Ceremony June 10 – Carleton College News

Posted: at 11:59 am

Carleton College will award the Bachelor of Arts degree to the 505 graduating members of the Class of 2017 onSaturday,June 10, in a ceremony beginning at 9:30 a.m. on the lawn west of Hulings Hall on the Carleton campus. A celebratory picnic on the Bald Spot will follow. In the event of severe weather, commencement will be held indoors at the Recreation Center. Seating is available to accommodate all guests, whether outdoors or indoors, and no tickets are required. The ceremony will also be broadcasted live online (https://apps.carleton.edu/events/commencement/livestream/).

Following President Steve Poskanzers opening remarks,Reina Desrouleaux '17, chemistry major from Silver Spring,Maryland (whose speech is titled [insert meaningful life experience here]) and Eli Ruffer '17, chemistry major from Highland Park, Illinois (whose speech is titled Tyler, the Prospective Student)will address the Class of 2017, families and friends, and faculty. In additionally, Carleton College will confer an honorary doctorate upon Kathy L. Hudson 82, former Deputy Director for Science, Outreach, and Policy at the National Institutes of Health, who will briefly address the class.

The highest honor given by the College, conferred honoris causafor the sake of honorthis years honorary degree recipient is Dr. Kathy L. Hudson, former Deputy Director for Science, Outreach, and Policy at the National Institutes of Health (NIH).

Throughout her distinguished career, Hudson has served the public by ensuring that advances in genomics and other rapidly moving areas of medical research are paired with wise and effective public policies.

After earning a B.A. in biology from Carleton College and a M.S. in microbiology from the University of Chicago, Hudson obtained her Ph.D. in molecular biology from the University of California, Berkeley. Although she trained for a career in research, Hudson discovered that her real passion was science policy. As an American Association for the Advancement of Science (AAAS) Fellow in Washington DC, she worked for the U.S. House of Representatives and then the Congressional Office of Technology Assessment.

After a stint in the office of the Assistant Secretary for Health at the Department of Health and Human Services, Hudson joined the National Human Genome Research Institute (NHGRI) as assistant director. While there she made a compelling case to scientists, public policy experts, and lawmakers about the need for federal legislation to guard against genetic discrimination. She also helped to broker an historic agreement between the public and private human genome projects, which was announced by President Bill Clinton in the White House in 2000.

In 2002, Hudson left NHGRI to found and direct the Genetics and Public Policy Center at Johns Hopkins University. She became a leader in educating and advising about science and policy issues in genetics. Also at Hopkins, Hudson was an Associate Professor in the Institute of Bioethics and the Institute of Genetic Medicine. It was Hudson who did much of the work to assemble the talented and dedicated team that, in 2008 after years of effort, achieved passage of the landmark Genetic Information Nondiscrimination Act.

In 2009, Hudson returned to the National Institutes of Health, becoming the Deputy Director for Science, Outreach, and Policy. In that capacity helped found and launch the National Center for Advancing Translational Sciences. She also had a major hand in the design and launch of three national scientific projects the BRAIN Initiative, the Precision Medicine Initiative, and the Cancer Moonshot. In addition, she led efforts to revise the rules that govern participation of human subjects in research, modernize clinical trial reporting, expand scientific data sharing, and develop appropriate oversight for rapidly moving areas of medical research, including stem cells and gene editing.

On top of her many duties and responsibilities, Hudson made time to serve as a strong and tireless advocate for the role of women in science. She personally mentored a group of young women who are now moving into key leadership roles with a wide range of innovative biomedical research and policy initiatives.

Earlier this year Hudson left government service, and is working as an advisor to companies and research institutes as they forge new directions at the forefront of biomedical research.

For further information, including disability accommodations, contact the Carleton College Office of College Communications at(507) 222-4309or emailkraadt@carleton.edu. The commencement site is located on the Carleton campus between College and Winona Streets in Northfield.

Read the original here:
Carleton College to hold its 143rd Commencement Ceremony June 10 - Carleton College News

Posted in Gene Medicine | Comments Off on Carleton College to hold its 143rd Commencement Ceremony June 10 – Carleton College News

Page 1,776«..1020..1,7751,7761,7771,778..1,7901,800..»